Date: 2014-01-28
Type of information:
phase: 2
Announcement: initiation of the trial
Company: Adenovir Pharma (Sweden)
Product:
Action mechanism:
Disease: epidemic keratoconjunctivitis
Therapeutic area: Infectious diseases - Ophtalmological diseases
Country: Germany, Sweden
Trial details:
Latest
news: * On January 28, 2014, Adenovir Pharma has started a phase II clinical study for the treatment of a viral eye infection. Caused by adenoviruses, millions of people are infected every year by epidemic keratoconjunctivitis (EKC). There are currently no effective antiviral treatments available. Adenovir has already completed a clinical phase I study among 48 healthy volunteers and showed that the drug candidate is safe and well tolerated. Adenovir is now continuing the development of a pharmaceutical product for the treatment of EKC and has started a double-blind randomised phase II clinical study at six eye clinics in Sweden and Germany. Several patients have already been treated. In total the study may include up to 130 patients and is estimated to be completed in 2014.“This drug candidate takes a different and unique approach to treat the virus. If successfully developed, it could become the first effective antiviral treatment of EKC and it could solve a major medical problem,” says professor Gerd Geerling, University Eye Clinic in Düsseldorf, and in charge of the study at the German eye clinics.
